Drug Carriers Articles & Analysis: Older
14 news found
Oral thin films present a novel approach in drug delivery, offering ease in administration without the need for water and reducing risks associated with traditional dosage forms. ...
CD Formulation, a leader in biotechnological innovation, is advancing the field of targeted drug delivery with its customized metal-organic frameworks (MOFs) services. ...
Typically, the structures of such polymers are designed to reduce their dispersion in solution, thereby improving their stability and controllability. They’re widely used as drug carriers mainly because of their ability to efficiently carry and release drug molecules, thereby improving drug bioavailability and therapeutic ...
Microspheres, tiny spherical particles typically ranging from 1 to 100 microns in diameter, offer immense potential for targeted drug delivery. By encapsulating active pharmaceutical ingredients (APIs) within these microspheres, drugs can be delivered directly to specific tissues or organs, resulting in improved therapeutic efficacy and reduced side effects. ...
By leveraging cutting-edge conjugation methods, targeting drug delivery solutions, and RNAi delivery systems, scientists can gain unprecedented control over the design and synthesis of bioconjugates. ...
Various aspects such as the route of administration, dosage form, maximum and minimum doses, and the appearance of drug carriers, would be taken into consideration to achieve the most efficient and effective drug delivery. ...
For instance, nanoparticle-based drug delivery has become research of interest. More recently, CD Formulation, a trust worthy CRO partner for pharmaceutical companies worldwide, announced its commitment to developing suitable drug carriers by incorporating the power of nanotechnology. ...
API Chemical Modification Services The API chemical modification services include pH modification of drug molecules, drug salt formation, drug PEGylation, and different groups of precursor drug design. ...
The small molecule, precisely-dosed, delivered to the affected area through a proprietary drug-eluting carrier, stimulates stem cells, activating cells to grow healthy bone known as “osteoblasts”, and inhibits cells associated with bone degradation called “osteoclasts”. ...
The bioconjugate is based on CIS Pharma’s polymer drug carrier technology and is developed to diagnose and treat B7H3-positive forms of cancer. ...
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, a private, ...
Exosomes and their cargos may serve as cancer prognostic markers, therapeutic targets or even as anticancer drug-carrier. Exosome display is an innovative methodology enabling the manipulation of exosome protein content by the identification of addressing domains that mediate the specific distribution of proteins on exosomes. ...
CIS Pharma successfully completed the biodistribution study with its polymer carrier technology applied to an antibody radionuclide conjugate (ARC). The conjugate was tested in a SKOvip mouse model, an aggressive form of ovarian cancer. The ARC tested comprised Trastuzumab as a model antibody to which two polymer carriers were conjugated that contained several chelators for the immobilization of ...
” TLS’s patented neutron source has been specifically designed for clinical BNCT use in a hospital facility and produces low-energy neutrons that neutralize tumors containing accumulated boron-10, a non-toxic, non-radioactive isotope that when administered to a patient selectively collects in cancer cells. Because the boron-10 carrier drug is highly ...